From the Desk of the CEO

Updates from FDA

Updates from FDA

On February 16, 2024, FDA approved the first medication indicated to help reduce allergic reactions to more than one type of food after accidental exposure. Xolair (omalizumab—Genentech) injection is approved for the reduction of type I allergic reactions, including reducing the risk of anaphylaxis that may occur with accidental exposure to one or more foods in adults and children 1 year or older.

Lauren Howell, PharmD

Results of a COVID-19 vaccine safety study that included over 99 million patients from eight countries were released in February 2024.

John D. Grabenstein, RPh, PhD, FAPhA

Gabapentinoids, such as gabapentin and pregabalin, are commonly used in the management of epilepsy and neuropathic pain. However, these medications have recently come under scrutiny due to potential respiratory adverse effects, particularly in patients with COPD, which are characterized by progressive airflow limitation and recurrent exacerbations that impact a person’s quality of life.

Aiya Almogaber, PharmD